Sign In
Buy TLSA
$1.03
+0.0600 (+6.19%)
At Close: Jul 31, 2026
Tiziana Life Sciences' chief advisor to receive "Giants of MS" award
09:21am, Thursday, 30'th May 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the Chairman of its Scientific Advisory Board, Howard L Weiner, is to receive the “Giants of MS” award. The award ceremony will be held on May 30, 2
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
07:00am, Thursday, 30'th May 2024
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies v
Tiziana eyes orphan drug designation for multiple sclerosis treatment
08:24am, Monday, 13'th May 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has requested its multiple sclerosis treatment be granted orphan drug designation by the Food and Drug Administration (FDA). Tiziana's intranasal foralumab wo
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
07:00am, Monday, 13'th May 2024
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies v
Tiziana Life Sciences unveils positive neuroimaging data for foralumab in MS patients
10:59am, Thursday, 25'th Apr 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled new neuroimaging data which shows its investigational drug intranasal foralumab improved White Matter Z-scores in patients with non-secondary progr
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
10:00am, Thursday, 25'th Apr 2024
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences wins FDA approval to add patients to Multiple Sclerosis Expanded Access Program
08:43am, Tuesday, 23'rd Apr 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has been approved by the US Food and Drug Administration to expand patient enrollment in its non-active Secondary Progressive Multiple Scleros
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences reports additional positive results from Multiple Sclerosis program
08:49am, Monday, 22'nd Apr 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled additional positive results from its Expanded Access Program for patients with non-active secondary progressive multiple sclerosis (na-SPMS). The c
NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences' foralumab study highlighted in Neurology Today
09:09am, Friday, 19'th Apr 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its study on foralumab, the company's lead candidate, was published in Neurology Today, the esteemed news source of the American Academy of Neurology (AAN)
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) - - Data presented in a platf
Tiziana Life Sciences says foralumab shows promise in stabilizing certain types of MS
09:30am, Thursday, 18'th Apr 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) unveiled new quantitative PET imaging data on foralumab at the Annual Meeting of the American Academy of Neurology in Denver. The company presented data from it
Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans Oral pr
Tiziana Life Sciences to present new imaging data for lead asset at upcoming neurology conference
09:11am, Thursday, 11'th Apr 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will be presenting new data about its lead clinical asset foralumab at the Annual Meeting of the American Academy of Neurology being held from
